Update shared on01 Aug 2025
As Avadel Pharmaceuticals’ consensus analyst price target, future P/E, and consensus revenue growth forecasts all remained effectively unchanged, the fair value assessment holds steady at $17.25.
What's in the News
- ASL Strategic Value Fund LP has urged shareholders to vote against Avadel's board nominees and called for an independent election monitor at the upcoming annual meeting, citing concerns about past vote counting procedures.
- ASL Strategic Value Fund has also pressed the board to explore monetizing LUMRYZ, referencing the drug’s recent orphan drug designation for idiopathic hypersomnia (IH), which could add $500 million to $1 billion in annual revenue if approved for this indication.
- The U.S. Court of Appeals affirmed the FDA’s approval of LUMRYZ, rejecting Jazz Pharmaceuticals’ legal challenge and upholding Avadel’s market position.
- The U.S. Court of Appeals for the Federal Circuit overturned key injunctions related to LUMRYZ, allowing Avadel to pursue new indications beyond narcolepsy and continue clinical trials for IH.
- Avadel raised its 2025 full-year net product revenue guidance to $255–$265 million and presented new supportive LUMRYZ data at a major sleep medicine conference.
Valuation Changes
Summary of Valuation Changes for Avadel Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at $17.25.
- The Future P/E for Avadel Pharmaceuticals remained effectively unchanged, at 14.13x.
- The Consensus Revenue Growth forecasts for Avadel Pharmaceuticals remained effectively unchanged, at 28.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.